A part of Merck

HND1MAG-39K | MILLIPLEX MAP Human Neurological Disorders Magnetic Bead Panel 1 - Neuroscience Multiplex Assay

Diseñe y calcule el precio de su kit
Click To Print This Page


Replacement Information

Tabla espec. clave

Analytes AvailableSpecies ReactivityKey ApplicationsDetection Methods
α-Synuclein, NGF-β, NSE, PARK5/UCHL1, PARK7/DJ-1, Tau (pThr231), Tau (Total) H Mplex Luminex xMAP
Catalogue NumberHND1MAG-39K
Trade Name
DescriptionMILLIPLEX MAP Human Neurological Disorders Magnetic Bead Panel 1 - Neuroscience Multiplex Assay
OverviewThe MILLIPLEX® MAP Human Neurological Disorders Magnetic Bead Panel 1, coupled with the Luminex® xMAP® platform in a magnetic bead format, enables you to focus on discovery so you receive the advantage of ideal speed and sensitivity, allowing quantitative multiplex detection of dozens of analytes simultaneously, dramatically improving productivity.
Background InformationNeurological disorders may be initiated by a number of diseases, or injury to the brain or spinal cord. Numerous potential biomarkers of neurological disorders have been identified. The ability to perform multiplexed analysis of these biomarkers offers a valuable research tool. The MILLIPLEX® MAP Human Neurological Disorders Magnetic Bead Panel 1 is to be used for the simultaneous quantification of the following 7 analytes in any combination in human cerebrospinal fluid (CSF):

• α-Synuclein
• NGF-β (Nerve Growth Factor, beta subunit)
• NSE (Neuron-Specific Enolase)
• PARK5/UCHL1 (Parkinson Disease Protein 5)
• PARK7/DJ1 (Parkinson Disease Protein 7)
• Tau (Thr231) (Phosphorylated Neurofibrillary Tangle Protein)
• Tau (total) (Neurofibrillary Tangle Protein)
Product Information
Detection methodLuminex xMAP
ConfigurationDesign your multiplex kit by choosing available analytes within this panel.
Precision, %
  • Intra-assay: < 15
  • Inter-assay: < 20
Panel TypeMAGNETIC Neuroscience
ApplicationThe analytes available for this multiplex kit are: α-Synuclein, NGF-β, NSE, PARK5/UCHL1, PARK7/DJ-1, Tau (pThr231), Tau (Total).
Key Applications
  • Multiplexing
Application Notes• This is an overnight assay.
• This assay requires 25 μL neat CSF per well.
Biological Information
Species Reactivity
  • Human
Analytes Available
  • α-Synuclein
  • NGF-β
  • NSE
  • PARK7/DJ-1
  • Tau (pThr231)
  • Tau (Total)
Assay PanelEverything you need in a single kit.
Cross ReactivityCross-reactivity between the antibodies and any of the other analytes in this panel is non-detectable or negligible.
  • 66% - 98%
Physicochemical Information
  • Refer to kit protocol for sensitivities of individual biomarkers.
Standard Curve Range
  • α-Synuclein 0.41 – 300 ng/mL
  • NGF-β 1.37 – 1000 pg/mL
  • NSE 0.14 – 100 ng/mL
  • PARK5/UCHL1 2.74 – 2000 ng/mL
  • PARK7/DJ1 2.74 – 2000 ng/mL
  • Tau (Thr231) 0.69 – 500 nM
  • Tau (total) 0.02 – 12 ng/mL
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Usage Statement
  • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Storage and Shipping Information
Storage ConditionsRecommended storage for kit components is 2 - 8°C.
Packaging Information
Material Size96-well plate
Transport Information
Supplemental Information



Protocol: Human Neurological Disorders Magnetic Bead Panel 1

Ficha datos de seguridad (MSDS)


Ficha técnica de seguridad del material (MSDS) 

Referencias bibliográficas

Visión general referenciasPub Med ID
Plasma proteins predict conversion to dementia from prodromal disease.
Hye A, Riddoch-Contreras J, Baird AL, Ashton NJ, Bazenet C, Leung R, Westman E, Simmons A, Dobson R, Sattlecker M, Lupton M, Lunnon K, Keohane A, Ward M, Pike I, Zucht HD, Pepin D, Zheng W, Tunnicliffe A, Richardson J, Gauthier S, Soininen H, K³oszewska I, Mecocci P, Tsolaki M, Vellas B, Lovestone S.
Alzheimers Dement. 2014 Nov;10(6):799- 807.e2 2014

25012867 25012867


Immunoassay and Multiplex Kits: Analyte Quarterly Vol. 2, 2016
The Power of Biomarker Analysis

Licencias necesarias e Información técnica

96 well Template 2 Up
96 well Template Single
Quality Control Ranges - Milliplex Human Neurological Disorders Magnetic Bead Panel 1

Ficha técnica

Full Service Custom-built Assays


MILLIPLEX MAP: Exercise, Signaling, and Your Brain
Inflammation in Neurodegenerative Diseases
Toxicology in drug discovery and development: Biomarkers and model organisms